Latest Inflammation News

Page 7 of 7
Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.
Ada Torres
Ada Torres
29 Jan 2025
Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.
Victor Sage
Victor Sage
24 Jan 2025
Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.
Ada Torres
Ada Torres
14 Jan 2025

Browse the archive

Full archive